| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3988750 | Journal of Cancer Policy | 2014 | 4 Pages |
Abstract
•Personalized medicine is a response to emerging technologies and commercialization.•Testing for high risk genes will not impact on global cancer rates.•Testing for low risk genes has little promise for preventing cancer.•The impact of new technologies should be evaluated from a population perspective.•Genetic tests will have most potential for impact if made available to all.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Steven A. Narod,